Anxiety, Stress and Sleep Problems in People With Early Onset Dementia
Launched by KU LEUVEN · Sep 23, 2022
Trial Information
Current as of July 06, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding and addressing anxiety, stress, and sleep problems in people who have early onset dementia, which means they were diagnosed before the age of 65. The researchers want to find out what these individuals need to help manage their emotional well-being and sleep issues. To do this, they will run a six-week program with weekly one-hour sessions in day care settings. The goal is to provide support that may help reduce anxiety and improve sleep for participants.
To be eligible for this study, participants must have a diagnosis of early onset dementia, but those with severe dementia will not be included. The trial is not yet recruiting participants, so if you or a loved one fits the criteria, keep an eye out for when it opens. This study aims to enhance the quality of life for those affected by early onset dementia by addressing important mental health aspects.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • diagnosed with early onset dementia before age of 65Y
- Exclusion Criteria:
- • severe dementia
About Ku Leuven
KU Leuven, a prestigious research university located in Belgium, is renowned for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, KU Leuven integrates cutting-edge research with clinical practice, facilitating the development of new therapeutic strategies and medical technologies. The institution's robust infrastructure and expertise in various fields, including biotechnology, pharmacology, and public health, position it as a leader in conducting high-quality clinical research that adheres to rigorous ethical standards and regulatory requirements. Through its clinical trials, KU Leuven aims to contribute significantly to the global biomedical landscape and enhance health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brussel, Flanders, Belgium
Gent, Oost Vlaanderen, Belgium
Patients applied
Trial Officials
Julie Vanderlinden, PhD
Principal Investigator
Odisee University of Applied Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials